Suggestions
Giordano Bottà PhD
CEO & Co-Founder at Allelica
Giordano Bottà PhD is the CEO and Co-Founder of Allelica, a company focused on advancing precision medicine to improve human health.1 He has a strong background in public health and genomics, holding a PhD in Public Health.
Professional Experience
As the CEO of Allelica, Dr. Bottà is actively involved in various aspects of the company's operations and outreach:
- He frequently presents at industry conferences and events, sharing insights on precision medicine and genetic biomarkers.24
- Dr. Bottà participates in discussions with pharmaceutical and biotech companies about the use of Polygenic Risk Scores (PRS) in clinical trials and target identification.5
- He is passionate about using new genetic biomarkers to accelerate and de-risk clinical trials for developing innovative therapies.3
Academic Background
Giordano Bottà's academic credentials include:
- A PhD, likely in Public Health or a related field.
- Association with Sapienza Università di Roma, though the exact nature of this connection is not specified in the provided information.1
Recent Activities
Dr. Bottà maintains an active professional presence, as evidenced by his LinkedIn activities:
- He presented at the Multiomics in Precision Medicine 2024 event, discussing Allelica's approach to precision medicine.2
- In February 2024, he participated in the MedLab Middle East 2024 Conference in Dubai.4
- He attended an event in London focused on using genetic biomarkers in clinical trials.3
Giordano Bottà's work at Allelica and his involvement in various industry events demonstrate his commitment to advancing the field of precision medicine and leveraging genetic information to improve healthcare outcomes.
Highlights
This is why we work hard every day to build a future where we'll all know our heart attack PRS like we know our blood cholesterol levels.
If PRS is available early in life, we would live in a world where heart attacks wouldn't catch us off guard and brutally change our lives.
Heart attacks are highly preventable if people at high risk are identified while plaques are still building in the arteries. It's a long and silent process.
We have tools to counteract this insidious disease when it is still subclinical. It's time to act.
"PRS strongly correlated with the clinical phenotypes of the family members, helping to potentially explain the differential atherosclerotic burden between the two sisters. In this context, there is no urgency for intensive pharmacotherapy for the unaffected sister."
We're proud to know that Allelica, Inc Multi-Ancestry CAD PRS has helped this family receive, and these two cardiologists prescribe, the most appropriate and precise treatment.
#precisionmedicine #heartattack #prevention #polygenicriskscore #allelica
Heading to #AACR in San Diego to attend the conference!
Super excited to learn about the latest progress in the fight against cancer.
If you're interested in discussing how Polygenic Risk Score accelerates clinical development to bring effective drugs to the market faster, send me a message. Let's connect!
#CancerResearch #DrugDevelopment #polygenicriskscore Allelica, Inc
